期刊
CANCERS
卷 15, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/cancers15030866
关键词
colorectal cancer; microbiota; dysbiosis; probiotics; chemotherapy; immunotherapy
类别
Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths worldwide. Gut microbiota play a significant role in promoting inflammation and tumor progression in CRC. Advances in next-generation sequencing technologies and metagenomics have provided new insights into the role of gut microbiota in CRC development and its potential applications in diagnosis, prevention, and treatment.
Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths worldwide. While CRC is thought to be an interplay between genetic and environmental factors, several lines of evidence suggest the involvement of gut microbiota in promoting inflammation and tumor progression. Gut microbiota refer to the similar to 40 trillion microorganisms that inhabit the human gut. Advances in next-generation sequencing technologies and metagenomics have provided new insights into the gut microbial ecology and have helped in linking gut microbiota to CRC. Many studies carried out in humans and animal models have emphasized the role of certain gut bacteria, such as Fusobacterium nucleatum, enterotoxigenic Bacteroides fragilis, and colibactin-producing Escherichia coli, in the onset and progression of CRC. Metagenomic studies have opened up new avenues for the application of gut microbiota in the diagnosis, prevention, and treatment of CRC. This review article summarizes the role of gut microbiota in CRC development and its use as a biomarker to predict the disease and its potential therapeutic applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据